Patents by Inventor Valery Novokhatny
Valery Novokhatny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9879246Abstract: The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.Type: GrantFiled: February 7, 2013Date of Patent: January 30, 2018Assignee: Grifols Therapeutics Inc.Inventors: Thomas P Zimmerman, Valery Novokhatny, Shan Jiang, James D Colandene
-
Publication number: 20150250987Abstract: Devices, systems, and methods for delivery of therapeutics, in particular thrombolytic agents, in particular plasmin, are provided. The devices, systems, and methods also provide for occlusion of a vessel or graft distal and/or proximal to a treatment zone. Also provided are devices, systems, and methods that trap emboli.Type: ApplicationFiled: May 6, 2015Publication date: September 10, 2015Inventors: Dean Chamberlain, Valery Novokhatny, David Fineberg
-
Patent number: 9028465Abstract: Devices, systems, and methods for delivery of therapeutics, in particular thrombolytic agents, in particular plasmin, are provided. The devices, systems, and methods also provide for occlusion of a vessel or graft distal and/or proximal to a treatment zone. Also provided are devices, systems, and methods that trap emboli.Type: GrantFiled: April 9, 2013Date of Patent: May 12, 2015Assignee: Grifols, S.A.Inventors: Dean Chamberlain, Valery Novokhatny, David Fineberg
-
Patent number: 8512980Abstract: Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: GrantFiled: May 3, 2012Date of Patent: August 20, 2013Assignee: Grifols Therapeutics Inc.Inventor: Valery Novokhatny
-
Patent number: 8420079Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: GrantFiled: September 1, 2011Date of Patent: April 16, 2013Assignee: Grifols Therapeutics, Inc.Inventors: Jennifer Hunt, Valery Novokhatny
-
Publication number: 20120276611Abstract: Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided.Type: ApplicationFiled: May 3, 2012Publication date: November 1, 2012Inventor: Valery Novokhatny
-
Patent number: 8231869Abstract: Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: GrantFiled: October 18, 2006Date of Patent: July 31, 2012Assignee: Grifols Therapeutics Inc.Inventors: Philip Scuderi, Jr., Vikram Arora, Jennifer A. Hunt, Valery Novokhatny, Stephen R. Petteway, Jr.
-
Patent number: 8182808Abstract: Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: GrantFiled: November 22, 2011Date of Patent: May 22, 2012Assignee: Grifols Therapeutics Inc.Inventor: Valery Novokhatny
-
Publication number: 20120093799Abstract: Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided.Type: ApplicationFiled: November 22, 2011Publication date: April 19, 2012Inventor: Valery Novokhatny
-
Patent number: 8101394Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: GrantFiled: November 25, 2008Date of Patent: January 24, 2012Assignee: Grifols Therapeutics Inc.Inventor: Valery Novokhatny
-
Publication number: 20110318812Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: ApplicationFiled: September 1, 2011Publication date: December 29, 2011Inventors: Jennifer A. Hunt, Valery Novokhatny
-
Patent number: 8034913Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: GrantFiled: April 21, 2005Date of Patent: October 11, 2011Assignee: Grifols Therapeutics Inc.Inventors: Jennifer A. Hunt, Valery Novokhatny
-
Patent number: 7871608Abstract: A method of treating a subject, the method including administring a composition that includes a reversibly inactivated acidfied plasmin substantially free of a plasminogen activator, in a low buffering capacity buffer, wherein the composition is a solution suitable for pharmacenutical use that can be raised to physiological pH by adding no more than about 5 volumes of serum to the solution relative to a volume of the solution.Type: GrantFiled: August 25, 2008Date of Patent: January 18, 2011Assignee: Talecris Biotherapeutics, Inc.Inventors: Thomas P. Zimmerman, Valery Novokhatny, Shan Jiang, James Colandene
-
Publication number: 20110003332Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: ApplicationFiled: November 25, 2008Publication date: January 6, 2011Applicant: Talecris Biotherapeutics, Inc.Inventor: Valery Novokhatny
-
Publication number: 20100304465Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: ApplicationFiled: April 21, 2005Publication date: December 2, 2010Applicant: Talecris Biotherapeutics, Inc.Inventors: Jennifer A. Hunt, Valery Novokhatny
-
Publication number: 20100047228Abstract: Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.Type: ApplicationFiled: October 18, 2006Publication date: February 25, 2010Inventors: Philip Scuderi, JR., Vikram Arora, Jennifer A. Hunt, Valery Novokhatny, Stephen R. Petteway, JR.
-
Publication number: 20080311105Abstract: The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.Type: ApplicationFiled: August 25, 2008Publication date: December 18, 2008Inventors: Thomas P. Zimmerman, Valery Novokhatny, Shan Jiang, James Colandene
-
Patent number: 6964764Abstract: Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.Type: GrantFiled: May 10, 2002Date of Patent: November 15, 2005Assignee: Talecris Biotherapeutics, Inc.Inventors: Thomas P. Zimmerman, Valery Novokhatny, Kyle A. Landskroner, Gary J. Jesmok, Kathryn K. Taylor
-
Publication number: 20030026798Abstract: Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.Type: ApplicationFiled: May 10, 2002Publication date: February 6, 2003Inventors: Thomas P. Zimmerman, Valery Novokhatny, Kyle A. Landskroner, Gary J. Jesmok, Kathryn K. Taylor
-
Publication number: 20030012778Abstract: The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.Type: ApplicationFiled: May 10, 2002Publication date: January 16, 2003Inventors: Thomas P. Zimmerman, Valery Novokhatny, Shan Jiang, James Colandene